Equities Analysts Issue Forecasts for CMPX FY2024 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Compass Therapeutics in a report issued on Tuesday, November 12th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.36) for the year, up from their previous forecast of ($0.42). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q4 2024 earnings at ($0.11) EPS, FY2025 earnings at ($0.33) EPS, FY2026 earnings at ($0.29) EPS and FY2027 earnings at $0.09 EPS.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03.

Several other equities analysts have also issued reports on CMPX. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Monday, September 16th. Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Wednesday, August 7th. Finally, Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $5.00 to $4.00 in a report on Friday.

Compass Therapeutics Stock Down 13.2 %

CMPX opened at $1.38 on Friday. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.34. The business has a fifty day simple moving average of $1.75 and a 200-day simple moving average of $1.42. The firm has a market cap of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC raised its stake in Compass Therapeutics by 195.4% in the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after buying an additional 112,614 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Compass Therapeutics during the 3rd quarter worth about $37,000. The Manufacturers Life Insurance Company acquired a new position in Compass Therapeutics in the third quarter valued at approximately $79,000. Intech Investment Management LLC purchased a new position in Compass Therapeutics in the third quarter valued at approximately $30,000. Finally, Rovin Capital UT ADV purchased a new position in shares of Compass Therapeutics in the 3rd quarter valued at $25,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.